
Safety & quality
Immunogenicity
Also found as: immunogenic · immune response · immune reactions
The tendency of a therapeutic substance to provoke an immune response against itself. FDA uses this definition for protein therapeutics.[1]
Source check: 2026-10-04 · Editorial method
How the research uses this term
One measurement used in research is anti-drug antibodies. The phase I thymosin β4 study collected blood to assess antibodies to its investigational preparation.[2]
Reading the evidence
An antibody response and its clinical consequences are separate questions. FDA explains that antibodies can alter a therapeutic protein's effects and can also cause complications; the consequences depend on the response and product.[1]
Used in our guides
Continue reading where this term appears.
- BPC-157Read the term in context
- GHK-CuRead the term in context
- TB-500Read the term in context
- IpamorelinRead the term in context
- Wolverine stackRead the term in context
References
Definitions and explanations are paraphrased. The source locations below identify the supporting passages and methods.
- FDA: Immunogenicity of Protein-based TherapeuticsPrimary agency reference · Definition
Source locations: General Overview.
- A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteersPrimary research · Human phase I trial · 2021DOI: 10.1111/jcmm.16693
Source locations: Trial design and Procedure.
Review status · PendingSource packet file
A_first_in_human_randomized_double_blind_single_and_multiple_dose_phase_34346165_PMC8419156.pdf